Risk, Patient, Quality of life, TSX Venture Exchange, SEDAR, Failure, Depression, Ischemic cardiomyopathy, Company, Patent, Amputation, Dilated cardiomyopathy, Intention, Clinical trial, Chronic obstructive pulmonary disease, Indian stock exchange, Ischemia, Transmyocardial revascularization, Safety, PAD, Legislation, Vascular dementia, COVID-19, HEM, OTC, Demand, Ulcer, Stem cell, Apple Inc. litigation, Research, CLI, News, Lawsuit, Pharmaceutical industry
Tuesday, September 14, 2021 - 2:10pm
Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
- Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
- A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
- Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
- This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.